Siebelink, Nienke M. http://orcid.org/0000-0003-4710-1071
Asherson, Philip http://orcid.org/0000-0003-2667-2254
Antonova, Elena
Bögels, Susan M.
Speckens, Anne E.
Buitelaar, Jan K. http://orcid.org/0000-0001-8288-7757
Greven, Corina U. http://orcid.org/0000-0002-5433-7878
Funding for this research was provided by:
H2020 Marie Sk?odowska-Curie Actions (643051 MiND)
Medical Research Council (MR/M021475/1, G0901245)
National Institutes of Health (AG046938)
European Commission (602768, 295366)
Article History
Received: 14 May 2018
Accepted: 12 January 2019
First Online: 13 February 2019
Compliance with ethical standards
:
: Siebelink, Antonova, Bögels, Speckens and Greven have no conflicts of interest. Asherson has received funding for research by Vifor Pharma, and has given sponsored talks and been an advisor for Shire, Janssen Cilag, Eli Lilly and Co., Flynn Pharma, and Pfizer, regarding the diagnosis and treatment of ADHD. Furthermore, in the past 3 years, Buitelaar has been consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Medice, Lundbeck, Shire, Roche, Novartis and Servier. He is not an employee, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties.
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all the individual participants included in the study.